Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M263Revenue (TTM) $M162Net Margin (%)-126.5Altman Z-Score-45.6
Enterprise Value $M447EPS (TTM) $-0.6Operating Margin %-119.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score4,128Pre-tax Margin (%)-126.5Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-20.0Quick Ratio0.4Cash flow > EarningsY
Price/Sales1.65-y EBITDA Growth Rate %-14.6Current Ratio0.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-140.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M478ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
MNKDFirst Eagle Investment 2013-03-31 Sold Out -0.0066%$2.31 - $3.56
$ 0.55-80%Sold Out0
MNKDFirst Eagle Investment 2012-12-31 Buy 0.01%$1.85 - $2.83
$ 0.55-75%New holding800,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MNKD is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Castagna MichaelChief Commercial Officer 2016-08-26Buy17,500$0.78-29.49view
Castagna MichaelChief Commercial Officer 2016-08-24Buy15,000$0.87-36.78view
Castagna MichaelChief Commercial Officer 2016-08-23Buy25,000$0.94-41.49view
PFEFFER MATTHEW JCEO, CFO, Director 2016-08-15Buy25,000$0.99-44.44view
Castagna MichaelChief Commercial Officer 2016-08-12Buy25,000$1-45view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2016-07-06Sell6,294$1.06-48.11view
Castagna MichaelChief Commercial Officer 2016-05-17Buy50,000$0.93-40.86view
Martens JuergenCorporate VP and COO 2015-05-21Buy20,000$4.57-87.96view
Edstrom HakanPresident & CEO 2015-04-24Sell73,460$4.83-88.61view
Edstrom HakanPresident & CEO 2015-03-27Sell73,460$5.21-89.44view

Press Releases about MNKD :

Quarterly/Annual Reports about MNKD:

News about MNKD:

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions Dec 01 2016
Short Sellers Grow More Aggressive on Major Biotechs Nov 28 2016
10 Most Shorted Nasdaq Stocks Nov 28 2016
MANNKIND CORP Financials Nov 17 2016
A Trump Victory Sparks Stock Market Surge Nov 14 2016
MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 14 2016
Sanofi Gets Hosed on MannKind Deal (SNY, MNKD) Nov 11 2016
Edited Transcript of MNKD earnings conference call or presentation 9-Nov-16 10:00pm GMT Nov 11 2016
Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi Nov 10 2016
MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing Nov 10 2016
Short Sellers Grow More Selective on Major Biotechs Nov 10 2016
The 6 Most Shorted Nasdaq Stocks Nov 10 2016
MannKind and Sanofi Reach Agreement on AFREZZA® Nov 09 2016
MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from... Nov 09 2016
MannKind and Sanofi Reach Agreement on AFREZZA® Nov 09 2016
MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)